A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab
We identified potential new adverse events associated with bimekizumab through disproportionate analysis of extensive real-world data from the FAERS database. These findings enable healthcare professionals and pharmacists to prioritize effective management of high-risk adverse events, optimize drug utilization in clinical settings, and enhance patient medication safety.
Authors
- Jialan Xu
- Xihui Yu
- Meiqing Yang
- Zhuomiao Lin
- Jiahong Zhong
Institutions
- Fujian Medical University (CN)
- Chinese University of Hong Kong (HK)
- Shantou University (CN)
- Meizhou City People's Hospital (CN)
- Second Affiliated Hospital of Shantou University Medical College (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-05
- DOI
- https://doi.org/10.3389/fphar.2025.1714173
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province